Logo image of MSPR

MSP RECOVERY INC (MSPR) Stock Fundamental Analysis

NASDAQ:MSPR - Nasdaq - US5537453087 - Common Stock - Currency: USD

0.6314  -0.05 (-6.74%)

Fundamental Rating

2

Taking everything into account, MSPR scores 2 out of 10 in our fundamental rating. MSPR was compared to 103 industry peers in the Health Care Providers & Services industry. MSPR may be in some trouble as it scores bad on both profitability and health. MSPR is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MSPR has reported negative net income.
MSPR had a negative operating cash flow in the past year.
In the past 5 years MSPR always reported negative net income.
MSPR had negative operating cash flow in 4 of the past 5 years.
MSPR Yearly Net Income VS EBIT VS OCF VS FCFMSPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M -400M -500M

1.2 Ratios

MSPR has a worse Return On Assets (-25.77%) than 86.41% of its industry peers.
Industry RankSector Rank
ROA -25.77%
ROE N/A
ROIC N/A
ROA(3y)-6.93%
ROA(5y)-37.77%
ROE(3y)-128.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MSPR Yearly ROA, ROE, ROICMSPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

The Gross Margin of MSPR (33.20%) is better than 62.14% of its industry peers.
In the last couple of years the Gross Margin of MSPR has declined.
The Profit Margin and Operating Margin are not available for MSPR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 33.2%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.71%
GM growth 5YN/A
MSPR Yearly Profit, Operating, Gross MarginsMSPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

1

2. Health

2.1 Basic Checks

MSPR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MSPR has less shares outstanding
Compared to 5 years ago, MSPR has less shares outstanding
The debt/assets ratio for MSPR is higher compared to a year ago.
MSPR Yearly Shares OutstandingMSPR Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 1B 2B 3B
MSPR Yearly Total Debt VS Total AssetsMSPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

Based on the Altman-Z score of -1.72, we must say that MSPR is in the distress zone and has some risk of bankruptcy.
MSPR's Altman-Z score of -1.72 is on the low side compared to the rest of the industry. MSPR is outperformed by 81.55% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.72
ROIC/WACCN/A
WACC0.33%
MSPR Yearly LT Debt VS Equity VS FCFMSPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 0.02 indicates that MSPR may have some problems paying its short term obligations.
MSPR has a Current ratio of 0.02. This is amonst the worse of the industry: MSPR underperforms 96.12% of its industry peers.
MSPR has a Quick Ratio of 0.02. This is a bad value and indicates that MSPR is not financially healthy enough and could expect problems in meeting its short term obligations.
MSPR has a Quick ratio of 0.02. This is amonst the worse of the industry: MSPR underperforms 96.12% of its industry peers.
Industry RankSector Rank
Current Ratio 0.02
Quick Ratio 0.02
MSPR Yearly Current Assets VS Current LiabilitesMSPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

6

3. Growth

3.1 Past

The earnings per share for MSPR have decreased strongly by -626.43% in the last year.
Looking at the last year, MSPR shows a very strong growth in Revenue. The Revenue has grown by 34.77%.
MSPR shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.65% yearly.
EPS 1Y (TTM)-626.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.19%
Revenue 1Y (TTM)34.77%
Revenue growth 3Y7.65%
Revenue growth 5YN/A
Sales Q2Q%-86.05%

3.2 Future

Based on estimates for the next years, MSPR will show a very strong growth in Earnings Per Share. The EPS will grow by 147.54% on average per year.
Based on estimates for the next years, MSPR will show a very strong growth in Revenue. The Revenue will grow by 145.11% on average per year.
EPS Next Y145.1%
EPS Next 2Y147.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year197.69%
Revenue Next 2Y145.11%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MSPR Yearly Revenue VS EstimatesMSPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 10B 20B 30B 40B
MSPR Yearly EPS VS EstimatesMSPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 200 400 600 800 1K

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

MSPR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 0.00, the valuation of MSPR can be described as very cheap.
MSPR's Price/Forward Earnings ratio is rather cheap when compared to the industry. MSPR is cheaper than 100.00% of the companies in the same industry.
MSPR's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 34.61.
Industry RankSector Rank
PE N/A
Fwd PE 0
MSPR Price Earnings VS Forward Price EarningsMSPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MSPR Per share dataMSPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 100 -100 -200

4.3 Compensation for Growth

MSPR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MSPR's earnings are expected to grow with 147.54% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y147.54%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MSPR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MSP RECOVERY INC

NASDAQ:MSPR (8/13/2025, 2:13:46 PM)

0.6314

-0.05 (-6.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)08-07 2025-08-07
Earnings (Next)11-12 2025-11-12
Inst Owners6.41%
Inst Owner Change0%
Ins Owners26.2%
Ins Owner Change0%
Market Cap5.20M
Analysts82.86
Price TargetN/A
Short Float %16.22%
Short Ratio1.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0
P/S 0.4
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-263.65
EYN/A
EPS(NY)191.19
Fwd EY30279.93%
FCF(TTM)-2.9
FCFYN/A
OCF(TTM)-2.57
OCFYN/A
SpS1.59
BVpS-7.38
TBVpS-223.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.77%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 33.2%
FCFM N/A
ROA(3y)-6.93%
ROA(5y)-37.77%
ROE(3y)-128.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.71%
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.57%
Cap/Sales 20.98%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.02
Quick Ratio 0.02
Altman-Z -1.72
F-Score2
WACC0.33%
ROIC/WACCN/A
Cap/Depr(3y)1.07%
Cap/Depr(5y)43.68%
Cap/Sales(3y)23.63%
Cap/Sales(5y)15.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-626.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.19%
EPS Next Y145.1%
EPS Next 2Y147.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)34.77%
Revenue growth 3Y7.65%
Revenue growth 5YN/A
Sales Q2Q%-86.05%
Revenue Next Year197.69%
Revenue Next 2Y145.11%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y5.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y75.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y77.43%
OCF growth 3YN/A
OCF growth 5YN/A